BlackRock Increases Weigao Group Stake to 5.06%, Crossing Disclosure Threshold

BlackRock Inc. has increased its long position in Shandong Weigao Group Medical Polymer Company Limited (01066.HK), pushing its total stake above the key 5% disclosure threshold. The move signals a strengthened conviction from the world's largest asset manager in the Chinese medical device manufacturer.

Transaction Details

According to a filing with the Hong Kong Stock Exchange, the transaction occurred on July 31. The filing provided the following details:

• Shares purchased: 2,727,200
• Average price per share: HK$3.3812
• Total transaction value: Approximately HK$9.22 million (about US$1.18 million)

Updated Shareholding and Market Significance

Ad

Following the purchase, BlackRock's total holding in Weigao Group has increased to approximately 229 million shares. This new position represents a 5.06% stake in the company's issued share capital.

Crossing the 5% ownership level is a significant event for institutional investors under Hong Kong's market regulations, as it triggers a mandatory public disclosure requirement. This level of investment indicates a substantial position and makes BlackRock a notable shareholder, a development closely watched by other market participants.

Context

Shandong Weigao Group is a major producer of single-use medical devices, orthopedic materials, and blood purification products in China. An increased stake by a global institutional investor like BlackRock can be interpreted by the market as a vote of confidence in a company's valuation and long-term business prospects.